REGN7508 + Apixaban for Atrial Fibrillation

(ROXI-EVEREST Trial)

This trial tests a new drug, REGN7508, to evaluate its effectiveness compared to apixaban, a blood-thinning medication, in individuals with atrial fibrillation—a condition where the heart beats rapidly and unevenly. The trial aims to determine if REGN7508 is safe and effective in preventing strokes or blood clots. Researchers seek to identify potential side effects and assess whether the body reacts to the drug in ways that could reduce its effectiveness. The trial seeks participants diagnosed with atrial fibrillation who require ongoing blood-thinning treatment. As a Phase 3 trial, it represents the final step before FDA approval, offering participants an opportunity to contribute to potentially groundbreaking treatment advancements.

A previous study showed that REGN7508 holds promise for people with atrial fibrillation. Research indicates that this drug aims to prevent blood clots while maintaining low bleeding risks. Specifically, REGN7508 demonstrated a 7% rate of venous thromboembolism (VTE, or blood clots in veins) without causing major bleeding, suggesting that the drug is generally well-tolerated.

Apixaban, the comparator in the study, is already an approved treatment for atrial fibrillation, with well-understood side effects and risks from past use.

Most treatments for atrial fibrillation, like Apixaban, work by preventing blood clots through existing anticoagulant mechanisms. But REGN7508 is unique because it targets a different pathway entirely, potentially offering a novel approach to managing atrial fibrillation. Researchers are excited about this treatment because it could provide a new option for patients who may not respond well to current anticoagulants, offering hope for better management of the condition.

Research has shown that REGN7508 is a new drug under testing to determine its effectiveness in preventing strokes and blood clots in people with atrial fibrillation, a condition that causes an irregular heartbeat. Although limited data from human trials exist, the drug aims to manage heart rhythm or prevent clot formation. In this trial, participants will receive either REGN7508 with a placebo or apixaban with a placebo. Apixaban is a well-known treatment that effectively reduces the risk of stroke and blood clots in people with atrial fibrillation. This study will compare REGN7508 with apixaban to assess if it offers the same or better protection against these issues.⁶⁷⁸⁹¹⁰